According to research, medications for osteoporosis denosumab, zoledronate and calcium are capable of providing protection against COVID-19.
It is believed that, this regimen could provide a 30 to 40 percent reduction in the rate of COVID-19 infection. Certain drugs efficient in the treatment of rheumatic diseases can positively interfere in the natural course of COVID-19, either by a reduction in infection rate or a reduction in to high infectivity and debilitation.
This study included three bone disease groups, osteoporosis, fribromyalgia and osteoarthritis making up a population of 2000 patients. Low incidence rate was observed amongst this group thus, prompting an investigation into the different treatments and the evolution of rheumatology patients with non-inflammatory diseases and their connection to SARS-CoV-2 infection, their evolution and need for hospitalization and mortality.
Deductions from the study are that some of these treatments may protect patients against infection by COVID-19, although further studies will be required to elicit and provide confirmation.
Zoledronate is capable of modulating the immune response and can stimulate its activity against SARS-CoV-2 Denosumab is a drug that targets RANK/RANKL a system involved in the balance of the skeletal system through the activation and differentiation of some of its cells. Inhibition of this system modifies the inflammatory response and acts on cytokenes, which play a key role in COVID-19 infection . Another common treatment duloxetine an antidepressant may positively reduce the effect of COVID-19.
It is believed that these medications are safe for use and should be used in management of COVID-19 infection, however further studies on a larger population are required to consolidate on these findings.